GBI Research
has released the pharma report: "Frontier Pharma: Psoriasis - Identifying
and Commercializing First-in-Class Innovation", which identifies and assesses
first-in-class innovation in the psoriasis development pipeline.
Over the
last decade, a greater understanding of the underlying pathophysiology of
psoriasis has increased emphasis on developing immuneomodulating therapies, as
opposed to largely symptomatic treatments. This is currently reflected in a
competitive market dominated by multiple disease-modifying biologic therapies
(inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation
Despite
this, there are significant unmet needs in the market, including safety
concerns regarding immunomodulation. This is a particularly important issue for
the long-term commercial and clinical success of psoriatic therapeutics,
especially for emerging biologics. Another unmet need is ease of drug
application, as biologic drug delivery is invasive and painful.
This allows
for pipeline programs that offer a more refined approach to immunomodulation
and ease of drug application to gain market share upon entry. In a pipeline of
over 200 programs, approximately one third exhibits a novel mechanism of
action. Innovative programs target a wide range of molecules implicated in
immune signaling, such as cytokines and B and T cell antigens.
Several
promising first-in-class therapies can selectively modulate specific subsets of
immune cells without compromising the entire immune system. In particular,
biologics that target a subset of T cells, which are strongly implicated in
autoimmune pathophysiology, could allow for specificity of immune suppression
and thereby reduce adverse side effects. Based on clinical trials,
IL-17-targeted therapies have demonstrated superiority over currently
established therapies in achieving advanced clinical endpoints.
Other agents
which activate regulatory arms of the immune system have also shown promising
clinical profiles. In addition, innovative programs that target molecules have
only recently gained recognition of their therapeutic value in the treatment of
psoriasis, including novel angiogenic proteins, signaling transduction proteins
and novel nuclear receptors. Despite their recent implication in disease
pathophysiology, many of these agents have also demonstrated clinical utility
in the treatment of psoriasis and are likely to contribute to a diversified
therapeutic landscape.
Scope
- A brief
introduction to psoriasis, including symptoms, pathophysiology, and overview of
pharmacotherapy
- The
changing molecular target landscape between market and pipeline and particular
focal points of innovation
- Overview
of how innovative products are contributing to the pipeline and market for
psoriasis
-
Comprehensive review of the pipeline for first-in-class therapies, analyzed on
the basis of phase distribution, molecule type, molecular target, and
administration route
- Identification
and assessment of first-in-class molecular targets with a particular focus on
early-stage programs of which clinical utility has yet to be evaluated, as well
as literature reviews on novel molecular targets
- Assessment
of the licensing and co-development deals for psoriasis therapies
Reasons to buy
-
Understanding of the focal shifts in molecular targets in the psoriasis
pipeline
-
Understanding of the distribution of pipeline programs by phase of development,
molecule type and molecular target
- Scientific
and clinical analysis of first-in-class developmental programs
- Assessment
of the valuations of licensed and co-developed psoriasis treatments
- A list of
the first-in-class therapies potentially open to deal-making opportunities.
- Analysis
of financial valuations on licensed or co-developed first-in-class therapies
and generics
About Us
Radiant Insights is a platform for companies
looking to meet their market research and business intelligence requirements.
We assist and facilitate organizations and individuals procure market research
reports, helping them in the decision making process. We have a comprehensive
collection of reports, covering over 40 key industries and a host of micro
markets. In addition to over extensive database of reports, our experienced
research coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For
more information visit: Radiant
Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog
URL: http://www.esorics2010.org/
No comments:
Post a Comment